- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03682627
Preventive Fenestration With and Without Clipping in Kidney Transplantation (PREFEN)
PREventive Effect of FENestration With and Without Clipping on Post-Kidney Transplantation Lymphatic Complications: PREFEN Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Recent improvements in transplantation techniques, organ matching systems, and modern immunosuppressive regiments have made kidney transplantation a routine operation with acceptable mortality and morbidity rates. Post-kidney transplantation morbidities include vascular and urological complications, and postoperative fluid collections. Perirenal fluid collections, such as urinomas, hematomas, and lymphoceles, are some of most frequent complications following Kidney transplantation, among which post-Kidney transplantation lymphatic collections, are most challenging complications.
The incidence of post-kidney transplantation lymphatic complications is up to 50% and the peak incidence of lymphocele is during the 6th postoperative week (range: 2 weeks to 6 months).
Lymphoceles are usually asymptomatic and identified incidentally by routine ultrasound examination. However lymphoceles may result in morbidities such as abdominal discomfort, impaired wound healing, and thrombosis. Post-kidney transplantation lymphatic complications may also affect graft function by putting pressure on the kidney, or by compressing the ureter or transplant vasculature. The frequency and consequences of post-transplantation lymphoceles make preventive measures highly desirable.
Various preventive methods have been proposed in the literature. Lymphoceles usually originate from unligated lymphatic vessels, therefore precise ligation of donor and recipient lymphatic vessels can reduce lymphocele formation. Compression therapy of the lower limb after kidney transplantation and appropriate immunosuppressive therapy may also reduce lymphocele formation. Some authors have used polymeric sealants/hemostatic biomaterials or povidone-iodine to prevent lymphocele formation. However, the effectiveness and cost-efficiency of these methods has not been conclusively proven. Use of drains in lymphocele prevention has also been previously suggested, but this method remains controversial. Peritoneal fenestration at the time of kidney transplantation is a simple method to prevent lymphocele formation. This method has been widely studied in treatment and prevention of lymphoceles following kidney transplantation. However, to the best of our knowledge, only one randomized controlled trial has been performed to investigate the impact of preventive fenestration in prevention of post kidney transplantation lymphatic complications. This study showed that the prevalence of fluid collections in the fifth postoperative week was significantly higher in the standard group compared to fenestration group. Also, 15.5% of patients in the standard group developed symptomatic lymphoceles requiring treatment during the first postoperative year, versus 3.0% in the fenestration group.
Recent studies have evaluated the effectiveness of extensive clipping using metallic clips following fenestration on lymphocele formation and lymph leakage after prostate cancer surgery and laparoscopic retroperitoneal lymph node dissection. Some surgeons have declared concerns that larger fenestrations increase the risk of hernia. However, risk of closure of the peritoneal fenestration is higher for smaller Windows in the peritoneal cavity. Recently clipping of the edges of peritoneal fenestration was performed in the surgical clinic of the Heidelberg University Hospital to reduce risk of closure of the fenestration after kidney transplantation. However, whether fenestration and clipping prevents lymphocele formation after kidney transplantation has not been investigated.
This clinical Trial is designed to investige the rate of post-kidney transplantation lymphocele and lymphorrhea in two groups of kidney transplantation patients: one with only fenestration and one with fenestration and clipping of the edges. Additionally, graft function and incidence rate of other morbidities will be investigated and analyzed after transplantation.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Baden-Württemberg
-
Heidelberg, Baden-Württemberg, Germany, 69120
- Division of Visceral Transplantation, Department of General, Visceral and Transplantation Surgery, University of Heidelberg
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age > 18 years
- Provide written informed consent
- Recipients of KTx from deceased donors
Exclusion Criteria:
- Inability to comply with study and/or follow-up procedures
- Recipients of KTx from living donors
- Combined transplantation (e.g. pancreas-kidney transplantation)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: preventive fenestration
Fenestration is performed at the time of kidney transplantation
|
A standardized fenestration of the peritoneum will be performed.
A 2 cm incision will be made in the peritoneum that is parallel to the skin incision after the transplant procedure.
The peritoneal will not be sutured at the edges to keep the fenestration open.
No interpositioning of the omentum will be performed.
|
Experimental: preventive fenestration and clipping
Fenestration and clipping of the edges are performed at the time of kidney transplantation
|
A standardized fenestration of the peritoneum will be performed.
A 2 cm incision will be made in the peritoneum that is parallel to the skin incision after the transplant procedure.
The window edges will be clipped after fenestration using 8 metal clips.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Post kidney transplantation lymphocele
Time Frame: 6 months
|
Fluid collection of variable size located near to the transplanted kidney in a non-epithelialized cavity.
The possibility that the accumulation of fluid is a hematoma, abscess, and urinoma will be ruled out after aspiration of the fluid.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Operation time
Time Frame: 1 day
|
From skin incision to skin closure
|
1 day
|
Estimated blood loss
Time Frame: 1 day
|
Blood loss during operation from skin incision to skin closure (mL)
|
1 day
|
Length of hospital stay
Time Frame: 6 months
|
From the time of the operation to time of discharge
|
6 months
|
Postoperative complications
Time Frame: 6 months
|
Postoperative complications will be reported and classified according to the Clavien-Dindo classification.
|
6 months
|
Mortality
Time Frame: 90 days
|
Death due to any cause.
|
90 days
|
Post Kidney transplantation fluid collection
Time Frame: 6 months
|
Fluid accumulation near to the transplanted kidney will be diagnosed by ultrasound as routine of the Heidelberg
|
6 months
|
Post Kidney transplantation lymphorrhea
Time Frame: 6 months
|
Defined as an outflow of more than 50 (milileter) of fluid per day after the 7th post-KTx day.
Fluid that flows from the drain, or the site of the removed drain, or surgical wound, which is not blood, pus, or urine will be monitored
|
6 months
|
Lymphocele size
Time Frame: 6 months
|
Lymphocele diameter and volume will be recorded by ultrasound examination in mL.
|
6 months
|
Lymphocele symptomes
Time Frame: 6 months
|
6 months
|
|
Lymphocele/lymphorrhea severity grade
Time Frame: 6 months
|
Severity of lymphocele/lymphorrhea will be graded based on the applied management strategy (Grade A: Observation, Grade B: Non-surgical intervention, Grade C: Surgery).
|
6 months
|
Blood Urea Nitrogen Level
Time Frame: 6 months
|
Blood Urea Nitrogen Level (mg/dL)
|
6 months
|
Plasma uric acid Level
Time Frame: 6 months
|
Plasma uric acid Level (mg/dL)
|
6 months
|
Serum creatinine level
Time Frame: 6 months
|
Serum creatinine level (mg/dL)
|
6 months
|
Rate of delayed graft function
Time Frame: 30 days
|
Is defined as the need for one or more hemodialysis treatments following transplantation prior to the onset of graft function.
|
30 days
|
Glomerular filtration rate
Time Frame: 6 months
|
GFR (mL/min/1.73
m2) calculated with "175 × (Scr)-1.154
× (Age)-0.203
× (0.742 if female)" Formula
|
6 months
|
Rate of primary non-function grafts
Time Frame: 30 days
|
number of recipients whose grafts never functions after transplantation
|
30 days
|
Retransplantion rate
Time Frame: 6 months
|
Rate of retransplantation
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Arianeb Mehrabi, MD, Department of General, Visceral and Transplant Surgery, University Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- S-318/2017
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Transplantation
-
Astellas Pharma IncAstellas Pharma Europe B.V.CompletedKidney Transplantation | Renal Transplantation | Transplantation, Kidney | Grafting, Kidney | Transplantation, RenalBelgium, Germany, Spain, Sweden, Italy, Switzerland, United Kingdom, Austria, France, Poland, Czech Republic, Netherlands
-
Bristol-Myers SquibbCompletedKidney Transplantation: Transplantation, Kidney
-
Nantes University HospitalTerminated
-
Hospices Civils de LyonCompletedKidney Transplantation | Pancreas-kidney TransplantationFrance
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCzechia, France, Italy, Poland, United Kingdom
-
The Hospital for Sick ChildrenCompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCanada
-
Astellas Pharma Europe Ltd.TerminatedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationSpain, Australia, France, Germany, Canada, Italy, United Kingdom, Belgium, South Africa, Switzerland, Sweden, United States, Austria, Brazil, Czechia, Denmark, Finland, Hungary, Ireland, Mexico, Netherlands, New Zealand, Poland
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Medical University of ViennaUnknownKidney Function After Transplantation | Outcome After Kidney Transplantation
Clinical Trials on Fenestration
-
The Fourth Affiliated Hospital of Zhejiang University...Not yet recruiting
-
Oslo University HospitalCompletedIncidence of Symptomatic Lymphocele After Kidney Transplantation | Prevalence of Perirenal Fluid Collections at One, Five and Ten WeeksNorway
-
First Affiliated Hospital of Zhejiang UniversityRecruitingVascular Diseases | Aortic Dissection | Interventional Therapy | Left Subclavian Artery OcclusionChina
-
The University of Texas Health Science Center,...Robert Cizik Eye ClinicTerminated
-
Vanderbilt UniversityUnited States Department of DefenseCompleted
-
Kantonsspital AarauUnknownGlaucoma Open-AngleSwitzerland
-
Boston Children's HospitalCompletedSingle-ventricle | Hepatic CongestionUnited States
-
Shanghai Ninth People's Hospital Affiliated to...Enrolling by invitationType B Aortic DissectionChina
-
Mansoura UniversityTanta UniversityRecruiting
-
Shanghai Ninth People's Hospital Affiliated to...CompletedCystic Cavity Area Reduction Efficiency | the Recurrence of the Tumor